北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于上海毕得医药科技股份有限公司 2026 年第一次临时股东会的 法律意见书 国枫律股字[2026]A0051 号 致：上海毕得医药科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2026 年第一次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《上 海毕得医药科技股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会 议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事 ...

证券代码：688073 证券简称：毕得医药 公告编号：2026-006 上海毕得医药科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 9 日 （二） 股东会召开的地点：上海市杨浦区翔殷路 999 号 3 幢 6 层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 56 | | --- | --- | | 普通股股东人数 | 56 | | 2、出席会议的股东所持有的表决权数量 | 38,128,636 | | 普通股股东所持有表决权数量 | 38,128,636 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 44.2570 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 44.2570 | （四） 表 ...

2月9日，毕得医药大宗交易成交8.34万股，成交额475.2万元，占当日总成交额的7.65%，成交价57元， 较市场收盘价61.36元折价7.11%。 | 交易日期 | 证券調核 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 类出营业部 | 是否为专场 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-09 | 毕得医药 | 688073 | 57 | 270 | 4.74 | 是有限公司送路 | ្នកនិងចំនួន | | Ka | | 2026-02-09 | 毕得医药 | 688073 | 57 | 205.2 | 3.6 | 日本公司 2017年 | ទឹកនឹងដងដើ | | Ka | ...

Group 1 - The core transaction of Bid Pharma on February 5 involved 70,400 shares traded at a price of 57 yuan, totaling 4,007,400 yuan, which accounted for 6.43% of the total trading volume for that day [1] - The transaction price represented a discount of 7.44% compared to the market closing price of 61.58 yuan [1] - The trading was executed by Guangfa Securities and UBS, indicating active participation from major brokerage firms [2]

Market Performance - The medical services sector increased by 2.52% on February 3, with Norsig leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Top Gainers in Medical Services - Norsig (301333) closed at 78.98, up by 8.76% with a trading volume of 43,200 shares and a transaction value of 332 million [1] - Yinos (688710) closed at 61.07, up by 7.52% with a trading volume of 17,400 shares and a transaction value of 10.4 million [1] - Dean Diagnostics (300244) closed at 24.73, up by 6.69% with a trading volume of 447,200 shares and a transaction value of 1.084 billion [1] Market Capital Flow - The medical services sector saw a net inflow of 506 million from institutional investors, while retail investors experienced a net outflow of 4.12 billion [2][3] - The top stocks with significant institutional inflows included Tiger Medical (300347) with 103 million and Meinian Health (002044) with 86 million [3] Stock Performance Overview - The stock performance of various companies in the medical services sector showed a mix of gains and losses, with notable declines in stocks like Haocen Medical (002622) down by 1.97% [2] - The trading volume and transaction values varied significantly across different companies, indicating diverse investor interest [2]

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

| Public Prices were 1 kid LPS L | | | | | | | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | 奥出营业部 是否为专场 | | 026-02-02 | 毕得医药 | 688073 | 48 206.88 4.31 | 公司可能提高品 | Ki 發動產品 | 2月2日，毕得医药大宗交易成交4.31万股，成交额206.88万元，占当日总成交额的2.04%，成交价48 元，较市场收盘价58.28元折价17.64%。 ...

证券之星消息，1月30日医疗服务板块较上一交易日下跌1.77%，毕得医药领跌。当日上证指数报收于 4117.95，下跌0.96%。深证成指报收于14205.89，下跌0.66%。医疗服务板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 从资金流向上来看，当日医疗服务板块主力资金净流出11.47亿元，游资资金净流入3.55亿元，散户资金 净流入7.92亿元。医疗服务板块个股资金流向见下表： ...

上海毕得医药科技股份有限公司 2026 年第一次临时股东会会议资料 上海毕得医药科技股份有限公司 2026 年第一次临时股东会会议资料目录 | 2026 | 年第一次临时股东会会议须知 | 1 | | --- | --- | --- | | 2026 | 年第一次临时股东会会议议程 | 3 | | 2026 | 年第一次临时股东会会议议案 | 4 | | | 议案一：关于修订《董事、高级管理人员薪酬管理制度》的议案 4 | | 上海毕得医药科技股份有限公司 2026 年第一次临时股东会会议资料 证券代码：688073 证券简称：毕得医药 上海毕得医药科技股份有限公司 2026 年第一次临时股东会会议资料 2026 年 2 月 上海毕得医药科技股份有限公司 2026 年第一次临时股东会会议资料 上海毕得医药科技股份有限公司 2026 年第一次临时股东会会议须知 为维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证股东 会如期、顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东会规则》以及《上海毕得医药科技股份有限公司章程》等相关规 定，上海毕得医药科技股份有限公司（以下简称 ...

Group 1 - The core business of Shanghai Bid Pharma focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [2] - As of September 30, 2025, Bid Pharma achieved operating revenue of 979 million yuan, a year-on-year increase of 20.67%, and a net profit attributable to shareholders of 120 million yuan, up 42.79% year-on-year [2] - The company has distributed a total of 258 million yuan in dividends since its A-share listing [3] Group 2 - As of January 26, 2025, Bid Pharma's financing balance is 33.27 million yuan, accounting for 1.09% of its market capitalization, which is below the 30th percentile level over the past year [1] - On January 26, 2025, Bid Pharma had a net financing buy of -347,900 yuan, with a financing buy of 477,400 yuan and a financing repayment of 512,190 yuan [1] - The company has a total of 3,493 shareholders as of September 30, 2025, a decrease of 7.64% from the previous period, while the average circulating shares per person increased by 8.27% to 12,377 shares [2][3]